STAT+: Pharma’s ambitious antibiotic venture fund makes another investment
For only the second time since launching nearly two years ago, the AMR Action Fund…
Category: biotechnology
Listen: #JPM23, the future of Alzheimer’s, & rising Covid variants
What does 2023 have in store for biotech? How can the FDA win back trust?…
STAT+: Biogen shakes up R&D chief role, makes Singhal permanent replacement
More than a year after Al Sandrock was pushed out as Biogen’s R&D chief, the…
STAT+: Roivant-Pfizer inflammatory bowel drug hits high expectations in mid-stage study
An experimental inflammatory bowel disease medicine that serves as the basis for a partnership between…
STAT+: Geron, biotech that once sparked talk of immortality, finally gets a (more modest) success
Geron Corporation, a biotech that made sci-fi-sounding headlines through the 90s and 2000s before shuffling…
FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation
Congressional investigators sorted through more than 500,000 pages of documents from the Food and Drug…
STAT+: Pfizer says hemophilia B gene therapy significantly reduces bleeds
Pfizer said Thursday that its experimental gene therapy for hemophilia B significantly reduced the number…
STAT+: Get ready for ‘the electric vehicles of biopharma’: Three biotech trends to watch in 2023
Predicting the future is famously a mug’s game. Between Covid-19, drug pricing legislation, and a…
2022 in review, CEO indictments, & the year ahead
When does optimism become criminal? Why can’t biotech find its way back? And what’s going…
Gene therapy trial shows promise for treating ‘bubble boy’ syndrome. Now comes the hard part
H.T. Begay is a happy kid. He’s smiley, silly, and definitely trying to make you…
STAT+: Young private equity firm Catalio to absorb hedge fund HealthCor, capping off busy year of investment M&A
Two veterans of the health care investing world — Art Cohen and Joe Healey —…
CytoDyn’s former CEO indicted for securities fraud. His misleading statements hurt patients even more than investors
Beginning in 2018 and through 2021, CytoDyn and its former CEO Nadir Pourhassan told investors…
STAT+: The list of the worst biopharma CEOs of 2022: No ‘winner,’ just accountability
I enjoy thinking about and writing the Worst CEOs of Biopharma column every year. It’s…
Pharma wins changes in bill regarding FDA’s accelerated approval
A bill that makes it easier for the Food and Drug Administration to withdraw drugs…
STAT+: Gilead, Arcus anti-TIGIT drug reduces risk of lung cancer progression in mid-stage study
Gilead Sciences and Arcus Biosciences said Monday that an experimental cancer immunotherapy directed against a…
STAT+: Madrigal experimental drug delivers strong results in fatty liver disease known as NASH
Madrigal Pharmaceuticals said Monday that its experimental treatment for fatty liver disease improved liver biopsies…
STAT+: Even with gene therapy on the horizon, drugmakers join hunt for new sickle cell drugs
Next year, two curative gene therapies could be approved for sickle cell disease. Yet drugmakers…
.jpg)
STAT+: Here are the finalists for best biopharma CEO of 2022. And a winner
It’s that time of the year again when we at STAT recognize the Best Biopharma…
We finally have new drugs for sickle cell disease. Why are so few patients taking them?
At first, Lena Harvey didn’t realize anything had changed. She just started doing strange, unexpected…
STAT+: Drugmakers ask regulators to change standards on new Covid antibody drugs for most vulnerable
Biotech executives and a handful of academics pleaded with U.S. and European regulators on Thursday…
Listen: Leaky health data, ASH22, & what it takes to get booed by your peers
Why do billionaires get booed? How does Facebook end up with sensitive health data? And…
Virtual Event: “ASH Recap, Live!” 2022
Editor’s Note: A livestream of the event will be embedded below at 1 p.m. ET. …
STAT+: In bid to beat Bristol Myers, Takeda buys Nimbus’ anti-inflammatory drug drug for $4 billion
Takeda Pharmaceuticals said Tuesday it will spend $4 billion and offer another $2 billion in…
STAT+: Study points to new ‘king on the block’ for treatment of chronic lymphocytic leukemia
NEW ORLEANS – One of the best therapies for some types of lymphoma and leukemia…
STAT+: Moderna cancer vaccine reduces melanoma’s return by 44%
An experimental cancer vaccine being developed by the biotechnology firm Moderna and the drug giant…
STAT+: Mirati wins FDA approval for KRAS-blocking lung cancer drug, but blockbuster sales hopes have dimmed
The Food and Drug Administration on Monday approved a second KRAS-blocking treatment for advanced lung…
STAT+: Roche pharmaceuticals CEO Bill Anderson to step down after four-year-tenure
Roche announced Monday that Bill Anderson, CEO of its pharmaceuticals division, will step down after…
STAT+: Affimed’s natural killer cell therapy has murky path forward despite encouraging results
NEW ORLEANS – An experimental immunotherapy from Affimed for patients with advanced Hodgkin lymphoma has…
Amgen’s $27.8 billion Horizon merger is latest industry bet on pricey rare disease drugs
Amgen said Monday it would purchase Horizon Pharmaceuticals for $27.8 billion, marking the latest bet…
STAT+: Argenx antibody drug benefits patients with platelet-destroying autoimmune disorder
NEW ORLEANS — An antibody treatment developed by the Belgian drugmaker Argenx raised platelet counts…
STAT+: Emerging class of genetically targeted drugs induce remissions in leukemia patients
NEW ORLEANS — An emerging class of genetically targeted drugs is inducing remissions in about…
STAT+: Progress report on Adicet’s ‘gamma-delta’ T cell therapy shows mixed results on durability of remissions
NEW ORLEANS — Adicet Bio generated a good deal of buzz last June with a…
The ‘electric vehicles’ of pharma, Illumina’s boondoggle, & a Theranos sentencing
Who gets dibs on in-demand medicines? Can you get a refund on an $8 billion…
‘All the tech in the world doesn’t solve this’: Rare disease experts push biopharma on equity
Over the past few years, the biopharmaceutical industry has revved up efforts to diversify clinical…
STAT+: Could Vertex’s cystic fibrosis medicines hold a clue to treating deadly pneumonia?
About a year ago, a grad student came running up to Wolfgang Kuebler, looking all…
STAT+: Prometheus’ inflammatory bowel drug succeeds in two mid-stage trials
An investigative medicine from Prometheus Biosciences met its goals in a pair of Phase 2…
Eli Lilly tightens access to diabetes drug, frustrating some people with obesity
Touted by celebrities, raved about by TikTok users and advertised by med spas, a new…
STAT+: “This is not a cure”: Consensus begins to emerge on new Alzheimer’s drug
NEW YORK — A consensus may be emerging about how to prescribe the new Alzheimer’s…
STAT+: Gossamer drug for lung hypertension achieves study goal but with subpar treatment effect
Gossamer Bio said Tuesday that its experimental drug for pulmonary arterial hypertension achieved the main…
STAT+: Karuna Therapeutics replaces its CEO, suggesting takeover unlikely soon
Karuna Therapeutics said Tuesday that its CEO, Steve Paul, will be replaced by Bill Meury,…
STAT+: Mirati’s KRAS-blocking lung cancer drug clears safety hurdle in combination study
Mirati Therapeutics said Monday that its KRAS-targeting cancer drug called adagrasib combined with another immunotherapy…
STAT+: Inside one startup’s quest to build proteins from scratch using artificial intelligence
A Somerville startup and an academic lab in Seattle say they have developed a way…
STAT+: Alzheimer’s researchers try out an unfamiliar sensation: optimism
SAN FRANCISCO — Scientific meetings about Alzheimer’s disease can be funereal affairs, with researchers from…
Listen: Wither PhRMA, Alzheimer’s treatment data revealed, and the first fecal microbiome drug approval
A big Alzheimer’s treatment data reveal. The first FDA-approved fecal microbiome drug. And a stinging…
STAT+: With early data and a possible advantage, Amgen enters the obesity drug race
Amgen released detailed data on Thursday suggesting an early-stage drug can induce significant weight loss…
STAT+: Roche’s failed Alzheimer’s studies lend weight to an emerging idea about potential treatments
SAN FRANCISCO — The failure of a once-promising Alzheimer’s disease medicine from Roche appears to…
FDA approves first microbiome drug from Ferring Pharmaceuticals
The Food and Drug Administration approved the first therapy using bacteria from stool samples to…
STAT+: Detailed data on Alzheimer’s therapy from Eisai, Biogen hold up to scientific scrutiny
SAN FRANCISCO — A closely watched new treatment for Alzheimer’s disease held up to scrutiny…
.jpg)
STAT+: Horizon Therapeutics in acquisition talks with Amgen, Janssen, and Sanofi
Amgen, Janssen, and Sanofi are in talks to acquire Horizon Therapeutics, the Irish drugmaker confirmed…
STAT+: mRNA startup Strand Therapeutics raises millions to test targeted cancer therapies
When Jacob Becraft addressed a bustling party of a hundred-plus employees, friends, and investors at…